Business Context and Reporting Period
This summary covers the Form 10-Q filed by Eli Lilly & Co for the quarterly period ended June 30, 2001. The company operates primarily in the pharmaceutical products segment, with a smaller, non-material animal health business. The reporting period reflects strong growth in key therapeutic areas including neurosciences, endocrinology, and oncology, though the company faces significant legal challenges regarding patent exclusivity for its blockbuster drug, Prozac.
Key Financial Metrics
| Metric | Q2 2001 | Q2 2000 | YTD 2001 | YTD 2000 |
|---|---|---|---|---|
| Net Sales | $3,033.5 million | $2,621.5 million | $5,839.2 million | $5,072.6 million |
| Net Income | $827.7 million | $666.2 million | $1,634.5 million | $1,511.7 million |
| Earnings Per Share (Diluted) | $0.76 | $0.61 | $1.50 | $1.38 |
| Gross Margin | 82.8% | 81.2% | 82.1% | 80.3% |
| Operating Cash Flow (YTD) | $1,547.6 million (vs. $1,455.3 million YTD 2000) | |||
| Total Debt | $3.33 billion (Short-term: $430.0M; Long-term: $2.898B) | |||
| Cash & Equivalents | $2,971.8 million (as of June 30, 2001) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16% in Q2 2001 and 15% YTD compared to 2000. Growth was driven by Zyprexa (+34% Q2), diabetes care products (+28% Q2), Evista (+25% Q2), and Gemzar (+49% Q2). This was partially offset by a 16% decline in anti-infectives sales due to competition.
- Profitability: Net income rose 24% in Q2 and 8% YTD. Gross margins improved due to the mix shift toward higher-margin products like Zyprexa and Gemzar.
- Unusual Items in 2000: Comparisons for the six-month period are impacted by a $214.4 million gain on the sale of Kinetra LLC and $91 million of Y2K-related wholesaler buying in Q1 2000. Excluding these, YTD 2001 net income increased 20% over adjusted 2000 results.
- Balance Sheet: Cash and cash equivalents decreased by $1.14 billion YTD, primarily due to a $1.85 billion purchase of investments, $603.3 million in dividends, and $362.9 million in share repurchases.
Guidance, Outlook, and Risks
Financial Expectations
- Full-Year 2001 EPS: Management expects earnings per share in the range of $2.76 to $2.84, excluding unusual items.
- Q3 & Q4 2001 EPS: Expected to be in the range of $0.63 to $0.67 per quarter, excluding unusual items.
- Expense Outlook: Marketing and administrative expenses are expected to rise in the high single digits; R&D expenses are expected to increase in the low double digits.
- 2002 Outlook: Anticipates single-digit sales and EPS growth.
Material Risks and Contingencies
- Prozac Patent Litigation: The U.S. Court of Appeals ruled the 2003 method-of-use patent for Prozac invalid. Generic fluoxetine entered the U.S. market in early August 2001. Lilly expects a "very substantial decline" in U.S. Prozac sales over the next 12 months. Prozac accounted for approximately 19% of consolidated worldwide sales in Q2 2001. Lilly is seeking Supreme Court review.
- Zyprexa Patent Litigation: Generic manufacturers (Zenith, Reddy) have filed ANDAs challenging Zyprexa patents. Lilly expects to prevail but notes an unfavorable outcome could materially impact results.
- Manufacturing Compliance: The company is implementing improvements following FDA warning letters regarding Good Manufacturing Practices (cGMP) at two plants. While no material financial impact is currently expected, failure to resolve issues could lead to production interruptions.
- Other Legal: Ongoing product liability lawsuits (DES, Prozac) and environmental remediation costs (Superfund) are accrued, with insurance recoveries estimated at $63.2 million.
Investor Verification Checklist
- Verify the timeline and volume of generic fluoxetine (Prozac) market entry and its specific impact on Q3 and Q4 sales.
- Monitor the status of the U.S. Supreme Court petition regarding the Prozac patent ruling.
- Track the progress of FDA inspections for the company's manufacturing facilities and its contract manufacturers (Lonza, Catalytica).
- Review the growth trajectory of Zyprexa and diabetes products to ensure they offset the projected Prozac decline.
- Confirm the execution of the $3 billion share repurchase program and the impact on diluted share count.